Search details
1.
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Prostate
; 81(10): 683-693, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33956343
2.
Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening.
Radiology
; 299(3): 494-507, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33904776
3.
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Genet Med
; 23(9): 1726-1737, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34113011
4.
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Am J Obstet Gynecol
; 225(1): 51.e1-51.e17, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33493488
5.
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res
; 22(1): 25, 2020 Feb 26.
Article
in English
| MEDLINE | ID: mdl-32102695
6.
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res
; 22(1): 8, 2020 01 16.
Article
in English
| MEDLINE | ID: mdl-31948486
7.
The Lancet Commission on prostate cancer: planning for the surge in cases.
Lancet
; 403(10437): 1683-1722, 2024 Apr 27.
Article
in English
| MEDLINE | ID: mdl-38583453
8.
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
PLoS Med
; 16(12): e1002998, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31860675
9.
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
Br J Cancer
; 121(2): 180-192, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31213659
10.
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Lancet Oncol
; 19(2): 169-180, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29337092
11.
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
Genet Med
; 20(12): 1575-1582, 2018 12.
Article
in English
| MEDLINE | ID: mdl-29565421
12.
Prostate cancer.
Lancet
; 387(10013): 70-82, 2016 Jan 02.
Article
in English
| MEDLINE | ID: mdl-26074382
13.
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Cancer Res Treat
; 161(1): 117-134, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27796716
14.
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
JAMA
; 317(23): 2402-2416, 2017 06 20.
Article
in English
| MEDLINE | ID: mdl-28632866
15.
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Br J Cancer
; 114(10): 1165-74, 2016 05 10.
Article
in English
| MEDLINE | ID: mdl-27070714
16.
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Breast Cancer Res
; 16(6): 3419, 2014 Dec 23.
Article
in English
| MEDLINE | ID: mdl-25857409
17.
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.
Hum Genet
; 133(3): 347-56, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-24162621
18.
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Hum Mol Genet
; 20(23): 4732-47, 2011 Dec 01.
Article
in English
| MEDLINE | ID: mdl-21890493
19.
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).
Hum Genet
; 132(1): 5-14, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23064873
20.
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Eur Urol
; 83(3): 267-293, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36494221